Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response

    Ruiwen Hu, Xiaodie He, Nan Gao, Ting He, Li Li, Tianwei Gu, Xin Gu, Cheng Ji
    TLDR Lowering HER2 levels with certain drugs may reduce metabolic syndrome risk in women.
    This study involving 532 female patients found a significant association between higher serum HER2 levels and the prevalence of metabolic syndrome (MS). Women with MS had higher HER2 levels (9.25 vs. 8.10 ng/mL) and exhibited increased central obesity, hypertension, and glucose and lipid metabolism abnormalities. The likelihood of MS increased with higher HER2 levels, with a detection rate rising from 31.30% in the lowest quartile to 72.39% in the highest. HER2 levels were also linked to the use of certain medications, suggesting HER2 as a potential biomarker and therapeutic target for MS. Further research is needed to confirm these findings and explore treatment implications.
    Discuss this study in the Community →